Case Control Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2021; 9(6): 1259-1270
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1259
New indicators in evaluation of hemolysis, elevated liver enzymes, and low platelet syndrome: A case-control study
Su-Ya Kang, Yun Wang, Li-Ping Zhou, Hong Zhang
Su-Ya Kang, Yun Wang, Li-Ping Zhou, Department of Obstetrics, Suzhou Affiliated Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215002, Jiangsu Province, China
Hong Zhang, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China
Author contributions: Kang SY, Wang Y, Zhou LP and Zhang H designed the research study; Kang SY, Wang Y and Zhou LP collected and analyzed the data; Kang SY wrote the manuscript; Zhang H reviewed the writing; All authors have read and approved the manuscript.
Supported by the People’s Well-being Project of Suzhou City, No. SS201710; the Clinical Expert Team Introduction Project of Suzhou City, No. SZYJTD201709; and the Research Project on Maternal and Child Health of Jiangsu Province, No. F202045.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Suzhou Affiliated Hospital of Nanjing Medical University [approval No. (2019)118].
Informed consent statement: All gravidae involved gave informed written consent.
Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. The authors declare that there is no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Ping Zhou, BSc, Doctor, Department of Obstetrics, Suzhou Affiliated Hospital of Nanjing Medical University, Suzhou Municipal Hospital, No. 206 Daoqian Street, Gusu District, Suzhou 215002, Jiangsu Province, China. zhoulpszslyy@163.com
Received: September 8, 2020
Peer-review started: September 8, 2020
First decision: December 8, 2020
Revised: December 16, 2020
Accepted: January 5, 2021
Article in press: January 5, 2021
Published online: February 26, 2021
Core Tip

Core Tip: Systemic inflammatory response (SIR) markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet distribution width (PDW) and red cell distribution width (RDW) have been widely investigated in preeclampsia (PE) and less analyzed in hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome. In this retrospective case-control study, SIR markers were compared among HELLP/PE patients and healthy gravidae. NLR, RDW, MPV and PDW were increased and PLR was decreased in HELLP syndrome. These parameters may become predictive and prognostic indicators and useful additions to the current diagnostic standard of HELLP syndrome, if confirmed by further more studies.